检索结果 - Chris H. Takimoto

  • Showing 1 - 20 results of 20
Refine Results
  1. 1
    Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

    Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes 由 Ricardo M. Attar, Chris H. Takimoto, Marco M. Gottardis

    出版 2009
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice

    Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice 由 Minalini Lakshman, Li Xu, Vijayalakshmi Ananthanarayanan, J. C. Cooper, Chris H. Takimoto, Irene Helenowski, Jill C. Pelling, Raymond C. Bergan

    出版 2008
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Identification of an RNA binding site for human thymidylate synthase.

    Identification of an RNA binding site for human thymidylate synthase. 由 Edward Chu, Donna Voeller, David M. Koeller, J C Drake, Chris H. Takimoto, Gladys F. Maley, Frank Maley, Carmen J. Allegra

    出版 1993
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

    Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer 由 Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target

    The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target 由 Chris H. Takimoto, Mark P. Chao, C. Parker Gibbs, Mark McCamish, J. Liu, J.Y. Chen, Ravindra Majeti, Irving L. Weissman

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors

    A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors 由 Muhammad Wasif Saif, Chris H. Takimoto, Monica Mita, Udai Banerji, Nicole Lamanna, Januario E. Castro, Susan O'Brien, Christopher Stogard, Daniel D. Von Hoff

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

    Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies 由 Mark P. Chao, Chris H. Takimoto, Dong Dong Feng, Kelly M. McKenna, Phung Gip, Jie Liu, Jens-Peter Volkmer, Irving L. Weissman, Ravindra Majeti

    出版 2020
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  8. 8
    An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors

    An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors 由 María L. Amador, Darin Oppenheimer, Sofía Perea, Anirban Maitra, G. Cusati, Christi Iacobuzio-Donahue, Sharyn D. Baker, Raheela Ashfaq, Chris H. Takimoto, Arlene A. Forastiere, Manuel Hidalgo

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

    Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin 由 Anthony W. Tolcher, Alain C. Mita, Lionel D. Lewis, Christopher R. Garrett, Elizabeth Till, Adil Daud, Amita Patnaik, K. Papadopoulos, Chris H. Takimoto, Pamela Bartels, Anne Keating, Scott Antonia

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

    A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies 由 Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy Chu, Nancy Wong, Christopher DesJardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-643... 由 Patricia LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A. Rudek, Chris H. Takimoto, Rachel Neuwirth, Dixie-Lee Esseltine, S. Percy Ivy

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

    Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia 由 Dongdong Feng, Phung Gip, Kelly M. McKenna, Feifei Zhao, Ofelia Mata, Timothy Choi, Jiaqi Duan, Kavitha Sompalli, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Mark P. Chao, James Y. Chen, Jie Liu, Jens-Peter Volkmer

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Org... 由 Ramesh K. Ramanathan, Merrill J. Egorin, Chris H. Takimoto, Scot C. Remick, James H. Doroshow, Patricia LoRusso, Daniel Mulkerin, Jean L. Grem, Anne Hamilton, Anthony J. Murgo, Douglas M. Potter, Chandra P. Belani, Michael Hayes, Bin Peng, S. Percy Ivy

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function 由 Chris H. Takimoto, Martin A. Graham, G. Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel Mulkerin, Percy Ivy, Merrill J. Egorin, Jean L. Grem

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

    Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab 由 Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol, Mark Basik, Christopher Harbison, Shujian Wu, Tai W. Wong, Xin Huang, Chris H. Takimoto, Andrew K. Godwin, Benjamin Tan, Smitha Krishnamurthi, Howard A. Burris, Elizabeth Poplin, Manuel Hidalgo, José Baselga, Edwin Clark, David J. Mauro

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

    Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function 由 Alain C. Mita, Christopher J. Sweeney, Sharyn D. Baker, Andrew Goetz, Lisa A. Hammond, Amita Patnaik, Anthony W. Tolcher, Miguel A. Villalona‐Calero, Alan Sandler, Tuhin K. Chaudhuri, Kathleen Molpus, Jane E. Latz, Lorinda Simms, Ajai K. Chaudhary, Robert D. Johnson, Eric K. Rowinsky, Chris H. Takimoto

    出版 2006
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

    Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas 由 Robert G. Maki, David R. D’Adamo, Mary Louise Keohan, Michael Saulle, Scott M. Schuetze, Samir D. Undevia, Michael B. Livingston, Matthew M. Cooney, Martee L. Hensley, Monica Mita, Chris H. Takimoto, Andrew S. Kraft, Anthony Elias, Bruce Brockstein, Nathalie E. Blachère, Mark Edgar, Lawrence H. Schwartz, Li-Xuan Qin, Cristina R. Antonescu, Gary K. Schwartz

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

    CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma 由 Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, Andres Forero, Nancy L. Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann S. LaCasce, Graham P. Collins, Thu Ha Tran, Judith Lynn, James Y. Chen, Jens-Peter Volkmer, Balaji Agoram, Jie Huang, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Mark P. Chao, Sonali M. Smith

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

    First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers 由 Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik, Sumit Shah, Sreenivasa R Chandana, Drew Rasco, A. Dimitrios Colevas, Timothy J. O’Rourke, Sujata Narayanan, Kyriakos P. Papadopoulos, George A. Fisher, Víctor M. Villalobos, Susan Prohaska, Maureen Howard, Muralidhar Beeram, Mark P. Chao, Balaji Agoram, James Y. Chen, Jie Huang, Matthew Axt, Jie Liu, Jens-Peter Volkmer, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Dana Supan, Heather A. Wakelee, Rhonda Aoki, Mark D. Pegram, Sukhmani K. Padda

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

    Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols 由 Tricia R. Cottrell, Michael T. Lotze, Alaa M. Ali, Carlo Bifulco, Christian M. Capitini, Laura Q.M. Chow, Anthony R. Cillo, Deborah Collyar, Leslie Cope, Julie S. Deutsch, Genia Dubrovsky, Sacha Gnjatic, Denise Goh, Susan Halabi, Gary Kohanbash, Holden T. Maecker, Saman Maleki Vareki, Sarah Mullin, Barbara Seliger, Janis M. Taube, Wim Vos, Joe Yeong, Kristin G. Anderson, Tullia C. Bruno, Codruța Chiuzan, Iván Díaz-Padilla, Elizabeth Garrett‐Mayer, Isabella C. Glitza Oliva, Paola Grandi, Elizabeth G. Hill, Brian P. Hobbs, Yana G. Najjar, Phyllis Pettit Nassi, Virgil Simons, Sumit K. Subudhi, Ryan J. Sullivan, Chris H. Takimoto

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: